© 2024 HSP News Service, L.L.C.
Scientists at Johns Hopkins have identified a molecular marker called Mig6 that appears to accurately predict longer survival—up to 2 years—among patients being treated with the EGFR inhibitors gefitinib (Iressa) and erlotinib (Tarceva). Results from the preliminary study were published ...
The U.S. Food and Drug Administration (FDA) today expanded the approved uses of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abraxane) to treat patients with late-stage pancreatic cancer. “Patients with pancreatic cancer are often diagnosed...
In a study reported in the Journal of the National Cancer Institute, Hannah Arem, MHS, PhD, of the National Institutes of Health, and colleagues analyzed the association between quality of diet according to the 2005 Dietary Guidelines for Americans—Healthy Eating Index 2005...
Researchers at Mayo Clinic in Florida have revealed the process by which pancreatitis—chronic inflammation of the pancreas—morphs into pancreatic cancer. They say their findings point to ways to identify pancreatitis patients at risk of pancreatic cancer and to potential drug therapies...
A new study by researchers Fox Chase Cancer Center has identified a disconnect between clinical trials that look at new treatments for metastatic pancreatic cancer and the patient population most likely to be diagnosed with the disease. Clinical trials typically enroll, and base their findings on,...
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
When given sequentially, two orally available experimental drugs—sapacitabine and seliciclib—worked together to elicit antitumor effects in patients with incurable BRCA-deficient cancers, according to phase I data presented at the AACR Annual Meeting 2013, held in Washington, DC, April...
A new diagnostic test that uses a technique known as metabolomic analysis may be a safe and easy screening method that could improve the prognosis of patients with pancreatic cancer through earlier detection. Researchers examined the utility of metabolomic analysis as a diagnostic method for...
Two Indiana University researchers have been awarded a multiyear, $3.2 million grant to develop and improve therapies for pancreatic cancer, the fourth leading cause of cancer death in the United States. Mark R. Kelley, PhD, Betty and Earl Herr Professor of Pediatric Oncology Research, and Melissa ...
Celgene International Sàrl announced on Tuesday that its phase III clinical trial of paclitaxel protein-bound particles for injectable suspension, albumin-bound (nab-paclitaxel, Abaraxane) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer...